<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345605</url>
  </required_header>
  <id_info>
    <org_study_id>RDCRN 5102</org_study_id>
    <secondary_id>U54HD061221</secondary_id>
    <nct_id>NCT00345605</nct_id>
  </id_info>
  <brief_title>Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Crossover Study of Sodium Phenylbutyrate and Low-Dose Arginine Compared to High-Dose Arginine Alone on Liver Function, Ureagenesis and Subsequent Nitric Oxide Production in Patients With Argininosuccinic Aciduria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brendan Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urea cycle disorders are inherited illnesses in which the body does not produce enough of the
      chemicals that remove ammonia, a byproduct of protein metabolism, from the blood stream.
      Elevated ammonia levels can lead to brain damage and death. Argininosuccinic aciduria (ASA)
      is a type of urea cycle disorder that is characterized specifically by high levels of
      argininosuccinic acid, a chemical involved in the urea cycle. People with ASA are at risk for
      serious liver damage, which may be due to the elevated levels of argininosuccinic acid.
      Sodium phenylbutyrate (Buphenyl-TM) is a drug that has been used to treat other types of urea
      cycle disorders. This study will evaluate whether Buphenyl-TM in conjunction with decreased
      arginine dose (in addition to a normal regimen of protein) will improve short-term liver
      function and decrease plasma citrulline and ASA levels in people with ASA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cause of liver damage in people with ASA is unknown. However, because ASA is the only
      urea cycle disorder that is characterized by both liver damage and elevated levels of
      argininosuccinic acid, researchers believe that the elevated acid levels cause the liver
      damage. Common treatments for urea cycle disorders include a low-protein diet and arginine
      supplementation, which, when combined, help to decrease ammonia levels in the blood.
      Buphenyl-TM may aid in lowering ammonia and argininosuccinic acid levels. Although
      Buphenyl-TM has been FDA-approved for use in people with some types of urea cycle disorders,
      there is little information on the effectiveness of the drug in children with ASA. This study
      will evaluate whether treatment of ASA patients with Buphenyl-TM in conjunction with lowered
      doses of arginine improves liver function as measured by short-term assessment of synthetic
      activity and the use of stable isotope tracers to assess ureagenesis and nitric oxide
      production.

      Initially, participants in this double-blind, placebo-controlled, crossover study will
      undergo a 3-day washout period during which no Buphenyl-TM will be given. They will then be
      randomly assigned to one of two groups: either Buphenyl-TM (500 mg/kg/day or 10 grams/m2) and
      arginine (100 mg/kg/day or 2 grams/m2)), or arginine alone (500 mg/kg/day or 10 grams/m2).
      Participants will remain on this initial treatment arm for 1 week, at the conclusion of which
      an assessment of hepatic synthetic function, ureagenesis, and nitric oxide production will be
      performed. After this assessment, participants will undergo a second 3-day washout and then
      crossover to the other treatment arm for 1 week. At the end of the 1-week treatment period, a
      second assessment will be performed. During the washout period before each treatment period,
      no Buphenyl-TM will be administered, and arginine will be administered at the standard
      therapeutic dose of 500 mg/kg/day or 10 grams/2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measures of Liver Function: AST and ALT</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
    <description>Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of Liver Function: PT and PTT</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
    <description>Prothrombin time (PT) and partial thromboplastin time (PTT) were measured PT measures factors I (fibrinogen), II (prothrombin), V, VII, and X, while PTT is a performance indicator of the efficacy of the common coagulation pathways.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of Liver Function: Coagulation Factors</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
    <description>Plasma levels of coagulation factors I and IX were used as measures of hepatic synthetic function since the treatment duration was short.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of Liver Function: INR</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
    <description>The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed. This is due to the variations between different batches of manufacturer's tissue factor used in the reagent to perform the test. The INR was devised to standardize the results. Each manufacturer assigns an ISI value (International Sensitivity Index) for any tissue factor they manufacture. The ISI value indicates how a particular batch of tissue factor compares to an international reference tissue factor. The ISI is usually between 1.0 and 2.0. The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Argininosuccinic Acid Levels</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arginine Levels</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea Production Rate</measure>
    <time_frame>Measured after each 1-week treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Argininosuccinic Aciduria</condition>
  <condition>Amino Acid Metabolism, Inborn Errors</condition>
  <condition>Urea Cycle Disorders</condition>
  <arm_group>
    <arm_group_label>HDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Arm
Wash-out then 7 days of:
Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Arm
Wash-out followed by 7 days of:
Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Phenylbutyrate</intervention_name>
    <description>None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine</description>
    <arm_group_label>HDA</arm_group_label>
    <arm_group_label>LDA</arm_group_label>
    <other_name>Buphenyl-TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered</description>
    <arm_group_label>HDA</arm_group_label>
    <arm_group_label>LDA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has confirmed diagnosis of ASA by amino acid or enzyme assay

          -  Has a history of adequate compliance to the diet and treatment

          -  Able to take oral or G-tube medication

          -  Able to perform 24 hour urine collection

          -  Agrees to travel to Baylor College of Medicine

          -  If female, of child bearing potential, and sexually active, agrees to use an
             acceptable method of birth control

          -  Greater than 5 years of age

        Exclusion Criteria:

          -  Has a history of congestive heart failure, severe renal insufficiency, or any
             condition that causes sodium retention or edema

          -  Currently taking Probenecid, Haloperidol, Valproate or oral corticosteroids

          -  Pregnant or lactating

          -  Currently being treated for an acute illness

          -  Has co-morbid associations causing difficulties in the detection of hyperammonemic
             episodes, liver damage, or difficulties in the diet compliance

          -  Has known hypersensitivity to sodium phenylbutyrate

          -  Has taken any experimental medication within the last 30 days

          -  Has renal insufficiency with creatinine greater than 1.5 mg/dl at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/ucdc/index.htm</url>
    <description>Click here for the Urea Cycle Disorders Consortium website</description>
  </link>
  <reference>
    <citation>Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology. 2003 Nov;229(2):409-14. Epub 2003 Sep 11.</citation>
    <PMID>12970464</PMID>
  </reference>
  <reference>
    <citation>Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, Qiu DK, Cao AP, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol. 2003 Nov;9(11):2574-8.</citation>
    <PMID>14606100</PMID>
  </reference>
  <reference>
    <citation>Scaglia F, Marini J, Rosenberger J, Henry J, Garlick P, Lee B, Reeds P. Differential utilization of systemic and enteral ammonia for urea synthesis in control subjects and ornithine transcarbamylase deficiency carriers. Am J Clin Nutr. 2003 Oct;78(4):749-55.</citation>
    <PMID>14522733</PMID>
  </reference>
  <reference>
    <citation>Lee B, Yu H, Jahoor F, O'Brien W, Beaudet AL, Reeds P. In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8021-6.</citation>
    <PMID>10869432</PMID>
  </reference>
  <reference>
    <citation>Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127-70. Review.</citation>
    <PMID>8794176</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <results_first_submitted>May 15, 2014</results_first_submitted>
  <results_first_submitted_qc>November 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2014</results_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Brendan Lee</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Argininosuccinic Acid Lyase Deficiency</keyword>
  <keyword>ASA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Argininosuccinic Aciduria</mesh_term>
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 subjects with argininosuccinic aciduria were recruited at Baylor College of Medicine from May 2008 to December 2010.</recruitment_details>
      <pre_assignment_details>patients were randomly assigned to one of the two arms HDA or LDA after treatment and an interval the same patients returned and received the crossover treatment LD or HDA depending.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose First</title>
          <description>High dose arm 3 day wash-out followed by 7 days of: Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA interval then: Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA</description>
        </group>
        <group group_id="P2">
          <title>Low Dose First</title>
          <description>low dose arm 3 day wash-out followed by 7 days of: Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA interval then: Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Arm 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Interval</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Arm 2, Opposite Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose Arginine vs Low-dose Arginine Plus Buphenyl</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measures of Liver Function: AST and ALT</title>
        <description>Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured.</description>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Arginine Plus Buphenyl</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine; a 3-day washout period; a 1-week treatment period of arginine alone.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Arginine Alone</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of arginine alone; a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Liver Function: AST and ALT</title>
          <description>Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured.</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="10.9"/>
                    <measurement group_id="O2" value="52" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="9.55"/>
                    <measurement group_id="O2" value="57.86" spread="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For sample size calculation, we used the means and standard deviation for PT, PTT. Assuming r=0.5 between two measurements from the same subject, 12 subjects would provide a power of 0.8 to detect a 10% reduction in primary endpoints at an alpha value of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Assuming r=0.5 between two measurements from the same subject, 12 subjects would provide a power of 0.8 to detect a 10% reduction in primary endpoints at an alpha value of 0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Argininosuccinic Acid Levels</title>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose Arginine Alone</title>
          </group>
          <group group_id="O2">
            <title>Low-dose Arginine Plus Buphenyl</title>
          </group>
        </group_list>
        <measure>
          <title>Argininosuccinic Acid Levels</title>
          <units>micromole/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="44" upper_limit="165"/>
                    <measurement group_id="O2" value="53" lower_limit="29" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arginine Levels</title>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose Arginine Alone</title>
          </group>
          <group group_id="O2">
            <title>Low-dose Arginine Plus Buphenyl</title>
          </group>
        </group_list>
        <measure>
          <title>Arginine Levels</title>
          <units>micromoles/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" lower_limit="83" upper_limit="197"/>
                    <measurement group_id="O2" value="53" lower_limit="41" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urea Production Rate</title>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose Arginine Alone</title>
          </group>
          <group group_id="O2">
            <title>Low-dose Arginine Plus Buphenyl</title>
          </group>
        </group_list>
        <measure>
          <title>Urea Production Rate</title>
          <units>micromoles/kg/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215" spread="56"/>
                    <measurement group_id="O2" value="97" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measures of Liver Function: PT and PTT</title>
        <description>Prothrombin time (PT) and partial thromboplastin time (PTT) were measured PT measures factors I (fibrinogen), II (prothrombin), V, VII, and X, while PTT is a performance indicator of the efficacy of the common coagulation pathways.</description>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Arginine Plus Buphenyl</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine; a 3-day washout period; a 1-week treatment period of arginine alone.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Arginine Alone</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of arginine alone; a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Liver Function: PT and PTT</title>
          <description>Prothrombin time (PT) and partial thromboplastin time (PTT) were measured PT measures factors I (fibrinogen), II (prothrombin), V, VII, and X, while PTT is a performance indicator of the efficacy of the common coagulation pathways.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" lower_limit="13.7" upper_limit="14.6"/>
                    <measurement group_id="O2" value="13.8" lower_limit="13.6" upper_limit="14.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.91" lower_limit="29.55" upper_limit="32.54"/>
                    <measurement group_id="O2" value="30.98" lower_limit="29.16" upper_limit="31.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measures of Liver Function: Coagulation Factors</title>
        <description>Plasma levels of coagulation factors I and IX were used as measures of hepatic synthetic function since the treatment duration was short.</description>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Arginine Plus Buphenyl</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine; a 3-day washout period; a 1-week treatment period of arginine alone.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Arginine Alone</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of arginine alone; a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Liver Function: Coagulation Factors</title>
          <description>Plasma levels of coagulation factors I and IX were used as measures of hepatic synthetic function since the treatment duration was short.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.22" spread="47.26"/>
                    <measurement group_id="O2" value="229.77" spread="62.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.33" spread="33.2"/>
                    <measurement group_id="O2" value="98.36" spread="21.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measures of Liver Function: INR</title>
        <description>The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed. This is due to the variations between different batches of manufacturer's tissue factor used in the reagent to perform the test. The INR was devised to standardize the results. Each manufacturer assigns an ISI value (International Sensitivity Index) for any tissue factor they manufacture. The ISI value indicates how a particular batch of tissue factor compares to an international reference tissue factor. The ISI is usually between 1.0 and 2.0. The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used.</description>
        <time_frame>Measured after each 1-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Arginine Plus Buphenyl</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine; a 3-day washout period; a 1-week treatment period of arginine alone.</description>
          </group>
          <group group_id="O2">
            <title>High Dose Arginine Alone</title>
            <description>Participants will undergo treatments in the following order: a 3-day washout period; a 1-week treatment period of arginine alone; a 3-day washout period; a 1-week treatment period of sodium phenylbutyrate (Buphenyl-TM) plus arginine</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Liver Function: INR</title>
          <description>The result (in seconds) for a prothrombin time performed on a normal individual will vary according to the type of analytical system employed. This is due to the variations between different batches of manufacturer's tissue factor used in the reagent to perform the test. The INR was devised to standardize the results. Each manufacturer assigns an ISI value (International Sensitivity Index) for any tissue factor they manufacture. The ISI value indicates how a particular batch of tissue factor compares to an international reference tissue factor. The ISI is usually between 1.0 and 2.0. The INR is the ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system being used.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="13.7" upper_limit="14.6"/>
                    <measurement group_id="O2" value="13.8" lower_limit="13.6" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during both of the 7 day treatment phases</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-dose Arginine Alone</title>
        </group>
        <group group_id="E2">
          <title>Low-dose Arginine Plus Buphenyl</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperammonemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sandesh Nagamani</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <email>nagamani@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

